Beranda › Kanker Saluran Empedu › Michigan
Uji klinis Kanker Saluran Empedu di Michigan
9 studi untuk Kanker Saluran Empedu mencari peserta di lokasi di Michigan.
Kota di Michigan
Teks studi resmi (Bahasa Inggris)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- Karmanos Cancer Center (Site 109), Detroit
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Ann Arbor
- Research Site, Detroit
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07221253Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Grand Rapids
Menerima pesertaFase 2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05489211Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Grand Rapids
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Henry Ford Cancer-Detroit, Detroit
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Des 2025 · NCT06065371A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- START Midwest, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Des 2025 · NCT06943521Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.